Connect Biopharma Holdings Limited (NASDAQ: CNTB) announced results from a 52-week Phase 3 study of rademikibart for moderate-to-severe atopic dermatitis ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE